<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03844932</url>
  </required_header>
  <id_info>
    <org_study_id>CYC-202</org_study_id>
    <nct_id>NCT03844932</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sublimity Therapeutics Holdco Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr. Falk Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sublimity Therapeutics Holdco Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study CYC-202 is a multicenter, randomized, double-blind, placebo-controlled, parallel-group
      study to evaluate the efficacy and safety of ST-0529 in subjects with moderately to severely
      active UC, defined as a score of 5 to 9 on the 3-Component Adapted Mayo Score (comprised of
      rectal bleeding, stool frequency and endoscopy sub-scores; score range 0-9).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of a Screening period, Treatment period and Follow-up. The Screening
      period is comprised of two separate in-clinic visits, SV1 and SV2. At the initial Screening
      visit (SV1), subjects will be required to provide written informed consent to participate in
      the study and will then be assessed for eligibility. Electronic diaries will be provided to
      subjects at this visit to use for the duration of the study in order to record information
      relating to their UC disease. Subjects will return to the clinic for their Screening
      endoscopic assessment (SV2). Ulcerative colitis disease activity for eligibility will be
      assessed using the 3-Component Adapted Mayo Score. Upon successful completion of the
      Screening period, subjects will return to the clinic for their Baseline visit.

      During the Treatment period, subjects will be evaluated in the clinic at Baseline (Day 1),
      Week 2, Week 4, Week 8, and Week 12 (End of Treatment Period). At Week 6 and Week 10,
      subjects will be contacted by telephone to assess Adverse Events (AEs), concomitant
      medication usage and study drug regimen adherence.

      Subjects who complete the 12-week Treatment period will attend the Week 16 End of Study (EOS)
      visit. Subjects who discontinue study drug and withdraw or are withdrawn from the study
      before the Week 12 visit will be requested to return to the clinic as soon as possible to
      complete an Early Termination (ET) visit.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 24, 2019</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study will investigate ST-0529 doses of 18.75 mg BID, 37.5 mg BID, or 75 mg BID, versus matching placebo BID.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>The study will be conducted as a double-blind study. Both the Investigator and subjects will be blinded with respect to the treatment the subject will receive. In addition, the central reader of the endoscopy assessment will be blinded to subject treatment for the entire study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Remission at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Stool frequency sub-score of ≤ 1 associated with a decrease ≥ 1 point from baseline, rectal bleeding sub-score of 0, and an endoscopic sub-score of ≤ 1 using the 3-Component Adapted Mayo Score.
The 3-Component Adapted Mayo Score is a measure of UC disease ranging from 0 to 9 points and consists of 3 sub-scores, each graded from 0 - 3 with higher scores indicating more severe disease. The sub-scores are stool frequency (0 - 3); rectal bleeding (0 - 3); findings of endoscopy (0 - 3).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Response at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>A decrease from baseline in the 3-Component Adapted Mayo Score of ≥ 2 points and ≥ 30%, with an accompanying decrease in the sub-score for rectal bleeding of ≥ 1 point or an absolute sub-score for rectal bleeding of ≤ 1.
The 3-Component Adapted Mayo Score is a measure of UC disease ranging from 0 to 9 points and consists of 3 sub-scores, each graded from 0 - 3 with higher scores indicating more severe disease. The sub-scores are stool frequency (0 - 3); rectal bleeding (0 - 3); findings of endoscopy (0 - 3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic Healing at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Endoscopic Healing (I) defined as an endoscopic sub-score of ≤ 1.
The endoscopic sub-score is part of the 3-Component Adapted Mayo score and ranges from 0 - 3, with higher scores indicating more severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corticosteroid-free clinical response at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Clinical response and achieving a corticosteroid-free status at Week 12 in subjects using oral corticosteroids at the Baseline visit. Clinical response is defined as a decrease from baseline in the 3-Component Adapted Mayo Score of ≥ 2 points and &gt; 30%, with an accompanying decrease in the sub-score for rectal bleeding of ≥ 1 point or an absolute sub-score for rectal bleeding of ≤ 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corticosteroid-free clinical remission at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Clinical remission and achieving a corticosteroid-free status at Week 12 in subjects using oral corticosteroids at the Baseline visit. Clinical remission is defined as a stool frequency sub-score of ≤ 1 associated with a decrease ≥ 1 point from baseline, rectal bleeding sub-score of 0, and an endoscopic sub-score of ≤ 1 using the 3-Component Adapted Mayo Score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in individual Adapted Mayo sub-scores at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The Adapted Mayo Score is a measure of UC disease ranging from 0 to 12 points and consists of 4 sub-scores, each graded from 0 - 3 with higher scores indicating more severe disease. The sub-scores are stool frequency (0 - 3); rectal bleeding (0 - 3); findings of endoscopy (0 - 3); and Physician's Global Assessment [PGA] (0 - 3).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Colitis, Ulcerative</condition>
  <arm_group>
    <arm_group_label>ST-0529 18.75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ST-0529: 18.75 mg orally twice daily (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ST-0529 37.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ST-0529: 37.5 mg orally twice daily (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ST-0529 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ST-0529: 75 mg orally twice daily (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: matching placebo orally twice daily (BID)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ST-0529</intervention_name>
    <description>ST-0529 utilizes SmPill® technology to encapsulate the otherwise insoluble cyclosporine in a presolubilized, lipid-based formulation.</description>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_label>ST-0529 18.75 mg</arm_group_label>
    <arm_group_label>ST-0529 37.5 mg</arm_group_label>
    <arm_group_label>ST-0529 75 mg</arm_group_label>
    <other_name>cyclosporine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female adult subjects 18 to 75 years old, inclusive.

          2. Willing to provide written informed consent and to be compliant with the schedule of
             study visits and protocol assessments.

          3. Diagnosis of UC established at least 3 months prior to the Baseline visit, by clinical
             and endoscopic evidence (colonoscopy or flexible sigmoidoscopy)

          4. Moderately to severely active UC defined as the 3-Component Adapted Mayo Score of 5-9,
             inclusive, with an endoscopic sub-score of ≥ 2 (from central reading), and a rectal
             bleeding sub-score of ≥ 1, as determined 10 days (± 3 days) prior to Baseline.

          5. Evidence of active UC, confirmed histologically (from local read), extending proximal
             to the rectum with ≥ 15 cm of involved colon.

          6. At Screening, a colonoscopy will be required if the subject has had extensive colitis
             or pancolitis of &gt; 8 years duration or left-sided colitis of &gt; 12 years duration but
             has not had a colonoscopy within 1 year of the initial screening date. If the subject
             has had a colonoscopy within 1 year of the initial screening date, a flexible
             sigmoidoscopy may be used.

          7. Subjects presenting at Screening with moderately to severely active UC demonstrating
             an inadequate response or loss of response or intolerance/medical contraindication to
             at least one of the following conventional therapies for UC:

             a. Corticosteroids:

             i. Signs and symptoms of active disease despite treatment with an adequate dose (e.g.,
             prednisolone &gt; 40 mg/day or equivalent) over a period of 4 weeks for oral therapy or
             intravenously (IV) for up to 1 week or ≥ 9 mg/day oral budesonide;

             OR

             ii. Unable to reduce corticosteroids below the equivalent of prednisolone 10 mg daily
             orally within 3 months of starting steroids or having experienced a relapse within 3
             months of stopping steroids;

             OR

             iii. History of, or current intolerance to corticosteroids (including, but not limited
             to Cushing's syndrome, osteopenia/osteoporosis, hyperglycemia, insomnia, infection).

             b. Immunomodulators:

             i. Signs and symptoms of active disease despite at least 3 months of treatment with a
             sufficient dose (oral azathioprine ≥ 1.5 mg/kg or 6-mercaptopurine [6-MP] ≥ 0.75
             mg/kg);

             OR

             ii. History of, or current dose-limiting toxicity associated with use of the agent
             (e.g., but not limited to nausea/vomiting, abdominal pain, pancreatitis, liver
             function test [LFT] abnormalities, lymphopenia, TPMT genetic mutation, infection).

             c. Anti-tumor necrosis factor (anti-TNF) agents:

             i. Signs and symptoms of active disease despite treatment with a single anti-TNF
             agent. Treatment failure is defined as a relapse after an initial response to therapy
             as follows:

               -  Infliximab: At least 4 infusions of at least 5 mg/kg within a 14-week timeframe
                  for induction and maintenance;

               -  Adalimumab: Induction regimen incorporating 160 mg at Week 0 (four 40 mg
                  injections in one day or two 40 mg injections per day for two consecutive days)
                  and 80 mg at Week 2, followed by maintenance treatment of 40 mg every other week
                  up to at least Week 8;

               -  Golimumab: Induction regimen incorporating 200 mg subcutaneous (sc) injection at
                  Week 0, followed by 100 mg at Week 2 and then maintenance treatment of 50 mg or
                  100 mg (weight dependent) every 4 weeks after completion of the induction regimen
                  up to at least Week 12;

             OR

             ii. History of, or current intolerance (with an initial response), defined as the
             presence of clinically significant side-effects, including infusion-related
             hypersensitivity.

             d. Vedolizumab:

             i. Signs and symptoms of active disease despite a history of at least one induction
             regimen, defined as at least a 14-week (10 weeks in the EU) induction consisting of
             300 mg IV at Weeks 0, 2 and 6.

             OR

             ii. History of intolerance to vedolizumab including, but not limited to, serious
             infections, hepatotoxicity, heart failure, allergic reactions, or any other condition
             that contributed to discontinuation of the agent.

          8. Subjects receiving oral corticosteroids for the treatment of UC must be on a stable
             dose of ≤ 40 mg/day (prednisolone or equivalent), or ≤ 9 mg/day budesonide. This dose
             must be stable from the initial Screening visit until 1 week after the initiation of
             study treatment.

          9. Subjects receiving oral 5-ASA must be on a stable dose from the initial Screening
             visit until the end of the study.

         10. Subjects willing to cease the use of any therapeutic enema or suppository or foams,
             other than that required in preparation for study-mandated colonoscopy/flexible
             sigmoidoscopies, from the initial Screening visit until the end of the study.

         11. Subjects willing to cease use of azathioprine or 6-MP from the initial Screening visit
             until the end of the study.

         12. Negative serum pregnancy test in females of childbearing potential at Screening.

         13. If female and of childbearing potential, must agree to be sexually abstinent or use
             one of the following highly effective methods of birth control from the initial
             Screening visit until 30 days after the last dose of study drug is administered:

               1. Hormonal contraceptives (e.g., combined oral contraceptives, patch, vaginal ring,
                  injectables, and implants);

               2. Intrauterine contraceptive system;

               3. Surgical sterilization or partner sterile (must have documented proof);

             AND

             One of the following effective methods of birth control:

               1. Male/female condom;

               2. Cervical cap with spermicide;

               3. Diaphragm with spermicide;

               4. Contraceptive sponge.

         14. Male subjects must be either surgically sterile (must have documented proof), agree to
             be sexually inactive or use a double-barrier method of birth control (e.g., condom and
             diaphragm with spermicide, condom with cervical cap and spermicide) from first study
             drug administration until 90 days after final drug administration.

        Exclusion Criteria:

        If a subject has any of the following criteria, they will be excluded from the study:

          1. Subjects without previous treatment for UC.

          2. Ulcerative colitis limited to rectum (ulcerative proctitis).

          3. Evidence of acute severe colitis with toxic megacolon, abdominal abscess, bowel
             stricture or bowel perforation.

          4. A diagnosis of Crohn's colitis, colitis yet to be classified, ischemic colitis,
             NSAID-induced colitis, idiopathic colitis (i.e., colitis not consistent with UC) or
             radiation colitis.

          5. Subjects with evidence of pathogenic bowel infection (Clostridium difficile,
             Escherichia coli, Salmonella, Shigella or Campylobacter).

          6. Previous surgery for UC or, in the opinion of the Investigator, will likely require
             surgery for UC during the study.

          7. Any histological evidence of mucosal dysplasia.

          8. Subjects with a current or recent history of severe, progressive or uncontrolled
             cardiac (including uncontrolled hypertension), renal, hepatic, hematological,
             gastrointestinal, metabolic, endocrine, pulmonary, cardiac or neurological (e.g.,
             history of seizures) disease, abnormal magnesium or potassium levels,
             hypocholesterolemia, or any other severe co-morbidity that, in the opinion of the
             Investigator, could confound the study results or put the study subject at
             unreasonable risk.

          9. Malignancies or history of malignancy within 5 years of the initial Screening visit,
             with the exception of adequately treated or excised non-metastatic basal cell
             carcinoma or squamous cell carcinoma of the skin.

         10. Any of the following laboratory abnormalities during the screening period - if values
             are initially outside the prescribed limits, the evaluation may be repeated once
             within the screening period to determine eligibility:

               1. Hemoglobin level &lt; 8.0 g/dL

               2. Absolute WBC count &lt; 3.0 × 10^9/L

               3. Absolute Lymphocyte count &lt; 0.5 × 10^9/L

               4. Absolute neutrophil count &lt; 1.2 × 10^9/L

               5. Platelet count &lt; 100 × 10^9/L or &gt;1200 × 10^9/L

               6. ALT or AST &gt; 2.0 × ULN

               7. Alkaline phosphatase &gt; 2.0 × ULN

               8. Serum creatinine &gt; 1.5 × ULN

               9. Bilirubin &gt; 1.5 × ULN

         11. Subjects with active TB infection or known history of prior treated or untreated TB
             infection.

         12. Subject with a positive serology test result for HIV (HIV type 1 or type 2).

         13. Subject with a positive serology test result for active HBV or HCV infection.

         14. Treatment with biologic agents for UC within 56 days or 5 half-lives (whichever is
             greater) prior to the Baseline visit.

         15. Treatment with any calcineurin inhibitor (e.g. cyclosporine or tacrolimus) within 28
             days prior to the Baseline visit.

         16. Treatment with methotrexate or JAK inhibitors (e.g. tofacitinib) from the initial
             Screening visit until the end of the study.

         17. Initiation of treatment with an oral or IV corticosteroid from the initial Screening
             visit until the end of the study.

         18. Use of any strong inhibitors of CYP enzymes (e.g., cimetidine, fluoxetine, quinidine,
             erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem, grapefruit juice
             and HIV antivirals) within 14 days prior to the Baseline visit.

         19. Use of strong or moderate P-gp inhibitors (e.g., amiodarone, azithromycin,
             clarithromycin, itraconazole, ketoconazole, dronedarone, lapatinib, quinidine,
             ranolazine, verapamil) within 14 days prior to the Baseline visit.

         20. Use of any herbal medication for the treatment of UC or which might interfere with CYP
             enzymes within 14 days prior to the Baseline visit.

         21. Subjects vaccinated with a live or live-attenuated vaccine within 14 days of the
             Baseline visit, or planned vaccination during conduct of the study.

         22. Subjects with a QTcF of &gt; 450 ms for males and &gt; 470 ms for females at Screening.

         23. A history of risk factors for Torsades de pointes (e.g., history of heart failure,
             hypokalemia, family history of Long QT Syndrome).

         24. Known hypersensitivity to cyclosporine or any excipients contained in ST-0529.

         25. History of alcohol or drug abuse in the year prior to the initial Screening visit.

         26. Subjects currently breast feeding, pregnant, or unwilling to delay initiation of
             breast feeding for at least 90 days after the last dose of study drug is administered.

         27. Participation in another clinical trial and having received investigational medication
             within 30 days or within 5 half-lives (whichever is longer) prior to the Baseline
             visit, or concurrent participation in another clinical trial.

         28. Subjects who, in the opinion of the Investigator, are unsuitable for inclusion in the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sponsor Responsible Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Sublimity Therapeutics (HoldCo) Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sublimity Therapeutics (HoldCo) Ltd</last_name>
    <phone>+1 619-333-8911</phone>
    <email>info@sublimitytherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sharp Chula Vista eStudy Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Waters, MD</last_name>
      <phone>619-955-5246</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Palmtree Clinical Research Inc</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Homan Abdollahzadeh, MD</last_name>
      <phone>760-778-7799</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alliance Clinical Research</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Merkes, MD</last_name>
      <phone>949-973-3704</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gastro Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Weiss, MD</last_name>
      <phone>727-336-7682</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jatin Bidani, MD</last_name>
      <phone>713-559-7351</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute, Inc.</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34653</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Curtis Freedland, DO</last_name>
      <phone>727-835-3261</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Endoscopic Research Inc</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henry Levine, MD</last_name>
      <phone>407-241-3229</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Spring Hill</city>
        <state>Florida</state>
        <zip>34609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atsushi Sakuraba, MD</last_name>
      <phone>773-834-7414</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IU Research, an Affiliate of Aerotek, Division of Gastroenterology/Hepatology</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sashidhar Sagi, MD</last_name>
      <phone>713-559-7351</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Houma Digestive Health Specialists, LLC</name>
      <address>
        <city>Houma</city>
        <state>Louisiana</state>
        <zip>70360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Capitol Research</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>AGA Clinical Reasearch Associates, LLC</name>
      <address>
        <city>Egg Harbor Township</city>
        <state>New Jersey</state>
        <zip>08234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barry Kaufman, MD</last_name>
      <phone>713-559-7351</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charlotte Gastroenterology &amp; Hepatology, PLLC</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Consultants for Clinical Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212-1375</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Spring Gastroenterology Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77002</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ravi Moparty, MD</last_name>
      <phone>281-888-5564</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manreet Kaur, MD</last_name>
      <phone>713-798-1468</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Biopharma Informatic, LLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Biopharma Informatic, LLC.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77084</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Maher, III, MD</last_name>
      <phone>281-944-3610</phone>
      <email>info@clinicalrc.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rio Grande Gastroenterology</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>HP Clinical Research</name>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <zip>84010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Gomel Regional Clinical Hospital</name>
      <address>
        <city>Gomel</city>
        <zip>246 029</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Mikhailova, MD</last_name>
      <phone>+375 296465206</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grodno Regional Clinical Hospital</name>
      <address>
        <city>Grodno</city>
        <zip>230017</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruslan Yakubtsevich, MD</last_name>
      <phone>+375 152434085</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>City Clinical Emergency Hospital</name>
      <address>
        <city>Minsk</city>
        <zip>220024</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalia Silivontchik, MD</last_name>
      <phone>+375 17 2878609</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Minsk Regional Clinical Hospital</name>
      <address>
        <city>Minsk</city>
        <zip>223041</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aliaksandr Varabei, MD</last_name>
      <phone>+375 17-265-22-13</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MedConsult Pleven</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Baydanov, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;Sveti Georgi&quot;</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksandar Petrov, MD</last_name>
    </contact>
    <contact_backup>
      <phone>+ 359 888544732</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medical Center Asklepion</name>
      <address>
        <city>Sofia</city>
        <zip>1303</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Draganova Raina, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMBAL Tsaritsa Joanna ISUL</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Plamen Penchev, MD</last_name>
      <phone>+359 29432103</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dalhousie University - Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Jones, MD</last_name>
      <phone>+1 9024734638</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terry Ponich, MD</last_name>
      <phone>+1 5196858500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Amiens Picardie - Service Hépato-Gastroentérologie</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathurin Fumery, MD</last_name>
      <email>fumery.mathurin@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU DE MONTPELLIER - Hôpital St ELOI</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume Pineton de Chambrun, MD</last_name>
      <phone>+33 467330165</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Saint-Etienne - Service de Gastro-Entérologie-Hépatologie</name>
      <address>
        <city>Saint-Étienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Roblin, MD</last_name>
      <email>xavier.roblin@chu-st-etienne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de Brabois Service d'Hépato-Gastro-Entérologie</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Peyrin-Biroulet, MD</last_name>
      <phone>+33 383157459</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eugastro GmbH</name>
      <address>
        <city>Leipzig</city>
        <state>Saxony</state>
        <zip>4103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingolf Schiefke, MD</last_name>
      <phone>+49 3414935720</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Walfriede, Akademisches Lehrkrankenhaus der Charite</name>
      <address>
        <city>Berlin</city>
        <zip>14163</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carsten Büning, MD</last_name>
      <phone>+49 3081810243</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Zentrym für Innere Medizin</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ursula Seidler, MD</last_name>
      <phone>+49 5115323306</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universität Leipzig, Klinik f. Gastroenterologie und Rheumatologie</name>
      <address>
        <city>Leipzig</city>
        <zip>4103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Hecker, MD</last_name>
      <phone>+49 89375089938</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>DRC Gyógyszervizsgáló Központ Kft.</name>
      <address>
        <city>Balatonfüred</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Istvan Szita, MD</last_name>
      <phone>+36 87481616</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <zip>1088</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zsolt Tulassay, MD</last_name>
      <phone>+36 14530980</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Semmelweis University, AOK Varosmajori Sziv- es Ergyogyaszati Klinika,</name>
      <address>
        <city>Budapest</city>
        <zip>H-1031</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gyula G Kiss, MD</last_name>
      <phone>+36 203997844</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bugat Pal Hospital</name>
      <address>
        <city>Gyongyos</city>
        <zip>3200</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gyula Horvat, MD</last_name>
      <phone>+36 37397833</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szent Borbála County Hospital</name>
      <address>
        <city>Tatabánya</city>
        <zip>2800</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>D07 RX49</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jen Leyden, MD</last_name>
      <phone>+353 7164596</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. James's Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Kevans, MD</last_name>
      <phone>+353 14103931</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Institute, Emek Medical Center</name>
      <address>
        <city>Afula</city>
        <zip>1834111</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eran Zittan, MD</last_name>
      <phone>+972 46495609</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barzilai Medical Center</name>
      <address>
        <city>Ashkelon</city>
        <zip>7830604</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ofer Ben Bassat, MD</last_name>
      <phone>+972 86745468</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clalit Health Services Jerusalem</name>
      <address>
        <city>Jerusalem</city>
        <zip>9362410</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Keret, MD</last_name>
      <phone>+97225457100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Gastroenterology, Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timna Naftali, MD</last_name>
      <phone>+972 97471017</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Humanitas Research Hospital, IBD Center</name>
      <address>
        <city>Milan</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvio Danese, MD</last_name>
      <phone>+39 3383014832</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo - Medicina Generale I</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Di Sabatino, MD</last_name>
      <phone>+39 236637105</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Rhodense - Ospedale di Rho</name>
      <address>
        <city>Rho</city>
        <zip>20017</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Saibeni, MD</last_name>
      <phone>+39 3479922595</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrizio Bossa, MD</last_name>
      <phone>+39 236637105</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Opieki Zdrowotnej Orkan-med</name>
      <address>
        <city>Ksawerów</city>
        <zip>95-054</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krystyna Stec-Michalska, MD</last_name>
      <phone>+48 226161488</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika Gastroenterologii</name>
      <address>
        <city>Lodz</city>
        <zip>90-647</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Gasiorowska, MD</last_name>
      <phone>+48 226161488</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medicome Sp. z o.o.</name>
      <address>
        <city>Oświęcim</city>
        <zip>32600</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Witold Zmuda, MD</last_name>
      <phone>+48 226161488</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Medyk</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-526</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafal Filip, MD</last_name>
      <phone>+48 509130097</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Endoskopia sp. z o.o.</name>
      <address>
        <city>Sopot</city>
        <zip>81-756</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marek Horynski, MD</last_name>
      <phone>+48 226161488</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>WIP Warsaw IBD Point Profesor Kierkus</name>
      <address>
        <city>Warszawa</city>
        <zip>00-728</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaroslaw Kierkus, MD</last_name>
      <phone>+48 226161488</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oddział Kliniczny Gastroenterologii Ogólnej i Onkologicznej SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego UM</name>
      <address>
        <city>Łódź</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ewa Małecka-Panas, MD</last_name>
      <phone>+48 226161488</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MedLife Grivita</name>
      <address>
        <city>Bucharest</city>
        <zip>010719</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ion Eugeniu Craciun, MD</last_name>
      <email>eugencraciun@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Colentina Clinical Hospital</name>
      <address>
        <city>Bucharest</city>
        <zip>020125</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radu Bogdan Mateescu, MD</last_name>
      <phone>+40 213152590</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Bucharest</name>
      <address>
        <city>Bucharest</city>
        <zip>050098</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucian Negreanu, MD</last_name>
      <phone>+40 722546405</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Center Tuculanu</name>
      <address>
        <city>Timişoara</city>
        <zip>300158</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Tuculanu, MD</last_name>
      <phone>+ 40 737502190</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Federal State Center of Coloproctology</name>
      <address>
        <city>Moscow</city>
        <zip>123423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexey Veselov, MD</last_name>
      <phone>+7 9067676741</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>LLC Medical center Healthy family</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalya Voloshina, MD</last_name>
      <phone>+7 9137575967</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191 124</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Gordienko, MD</last_name>
      <phone>+7 9523666484</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alliance Biomedical - Russian Group, LLC</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191014</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evgeny Soldatskiy, MD</last_name>
      <phone>+7 9075008140</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>North-Western State Medical University n.a. I.I.Mechnikov</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor Bakulin, MD</last_name>
      <phone>+7 8125439318</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scientific Research Center Eco-Safety LLC</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196143</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vasily Vasilyuk, MD</last_name>
      <phone>+7 9319683215</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pavlov First Saint Petersburg State Medical University</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vasily Trofimov, MD</last_name>
      <phone>+7 9533503467</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg State Medical Academy n.a. I.I. Mechnikov of Federal Agency of Healthcare &amp; Social Development</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>195067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yury Uspenskiy, MD</last_name>
      <phone>+7 9052096001</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Non state Public Health Institution &quot;Railway clinical hospital on station Samara&quot; of joint stock company Russian railways</name>
      <address>
        <city>Samara</city>
        <zip>403029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel Andreev, MD</last_name>
      <phone>+7 8123095457</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saratov State Medical University</name>
      <address>
        <city>Saratov</city>
        <zip>410054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yury Shvarts, MD</last_name>
      <phone>+7 8452560295</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Siberia State Medical University</name>
      <address>
        <city>Tomsk</city>
        <zip>630055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ekaterina Bukreeva, MD</last_name>
      <phone>+7 9039524868</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Center Zvezdara</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Svorcan, MD</last_name>
      <phone>+381 638022266</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical-Hospital Centre Bezanijska Kosa - Gastroenterology Department</name>
      <address>
        <city>Belgrade</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor Jovanovic, MD</last_name>
      <phone>+381 113010700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center &quot;Dr Dragisa Misovic-Dedinje&quot;</name>
      <address>
        <city>Belgrad</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Branka Filipovic, MD</last_name>
      <phone>+381 113538700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Center Kragujevac</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natasa Zdravkovic-Petrovic, MD</last_name>
      <phone>+381 113538700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IDIBGI, Hospital Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Aldeguer Mante, MD</last_name>
      <phone>+34 972940200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico Arguelles Arias, MD</last_name>
      <phone>+34 600162109</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chernivtsi Regional Clinical Hospital</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58001</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oleksandr Fediv, MD</last_name>
      <phone>+380 674800982</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankivsk National Medical University, Regional Clinical Hospital</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vira Vyshyvanyuk, MD</last_name>
      <phone>+38 342528010</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kharkiv City Clinical Hospital No 2 n.a. prof. O.O.Shalimov</name>
      <address>
        <city>Kharkiv</city>
        <zip>61037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olena Datsenko, MD</last_name>
      <phone>+380 674416147</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kiev City Clinical Hospital No. 1</name>
      <address>
        <city>Kiev</city>
        <zip>2091</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inna Markevych, MD</last_name>
      <phone>+38 0962274476</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Institution of Kyiv Regional Council &quot;Kyiv Regional Clinical Hospital&quot;</name>
      <address>
        <city>Kyiv</city>
        <zip>04107</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volodymyr Pyrogovskyy, MD</last_name>
      <phone>+380 676968964</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ukrainian-German Gastroenterology Center &quot;BYK-Kyiv&quot;</name>
      <address>
        <city>Kyiv</city>
        <zip>1030</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andriy Dorofeyev, MD</last_name>
      <phone>+38 0442359173</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Volyn Regional Clinical Hospital</name>
      <address>
        <city>Lutsk</city>
        <zip>43000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dmytro Shulga, MD</last_name>
      <phone>+38 0958969484</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Nonprofit Enterprise &quot;Lviv Clinical Emergency Care Hospital&quot;</name>
      <address>
        <city>Lviv</city>
        <zip>79059</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valeriy Vdovychenko, MD</last_name>
      <phone>+38 0951058009</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Nonprofit Entreprise, &quot;Lviv Clinical Emergency Care Hospital&quot;, 1st Therapeutic Dpt</name>
      <address>
        <city>Lviv</city>
        <zip>79059</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mykola Bychkov, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Nonprofit Enterprise &quot;Odesa Regional Clinical Hospital&quot;</name>
      <address>
        <city>Odesa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andriy Yurkiv, MD</last_name>
      <phone>+38 0674810508</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Nonprofit Enterprise &quot;Ternopil University Hospital&quot; of Ternopil Regional Council</name>
      <address>
        <city>Ternopil</city>
        <zip>46002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ihor Hospodarskyy, MD</last_name>
      <phone>+38 0509564218</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Municipal Institution &quot;Uzhhorod Central District Hospital&quot;</name>
      <address>
        <city>Uzhhorod</city>
        <zip>88009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan Chopey, MD</last_name>
      <phone>+380 31266494</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Center &quot;Health Clinic&quot;</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oleksandr Golovchenko, MD</last_name>
      <phone>+380 982267838</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Non-profit Enterprise &quot;Vinnytsia City Clinical Hospital #1&quot;</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Halyna Tomashkevych, MD</last_name>
      <phone>+38 0673324732</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miles Parkes, MD</last_name>
      <phone>+44 1223596461</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>South Eastern Health &amp; Social Care Trust, Ulster Hospital</name>
      <address>
        <city>Belfast</city>
        <state>Co Antrim</state>
        <zip>BT161RH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Allen, MD</last_name>
      <phone>+44 7713390302</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool &amp; Broadgreen University Hospitals NHS Trust</name>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Smith, MD</last_name>
      <phone>+44 1517064194</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <state>Warwickshire</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tariq Iqbal, MD</last_name>
      <phone>+44 1213718749</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Coventry &amp; Warwickshire NHS Trust</name>
      <address>
        <city>Coventry</city>
        <state>Warwickshire</state>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Barnsley Hospital NHS Foundation Trust</name>
      <address>
        <city>Barnsley</city>
        <state>Yorkshire</state>
        <zip>S75 2EP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Atkinson, MD</last_name>
      <phone>+44 1226435084</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE59RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy Chung-Faye, MD</last_name>
      <phone>+44 2032991435</phone>
    </contact>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 31, 2019</study_first_submitted>
  <study_first_submitted_qc>February 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2019</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

